Gogia A, Deo SVS, Sharma D, et al. - In this ambispective review, researchers determined the rates of discordance for the expression of biomarker—estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) — in patients with metastatic breast cancer in developing countries, such as India. In 103 patients with breast cancer (stage I, II, and III as per American Joint Committee on Cancer, 7th edition) who developed metastasis at recurrence, paired biomarker status was reviewed. At baseline and subsequent follow-up, biomarker status and clinical and radiologic parameters were reported. Findings revealed the presence of discordance in 21.3% for ER, 29.1% for PR, and 15.5% for HER2/neu receptor. They found that 7.8% had positive to negative ER and 13.6% negative to positive. They also identified positive to negative PR and negative to positive PR in 21.4% and in 7.8%, respectively. Positive to negative HER2/neu receptor and negative to positive was identified in nearly 6.8% and in 8.7%, respectively. Experts concluded that change in the tumor biology characterizes metastatic disease evolution in breast cancer and results in discordance in receptor status. It is justifiable to conduct repeat biomarker investigations at metastatic recurrence, particularly if management plans include hormone and targeted therapy.